Paraoxonase-1 activity in patients with cancer: A systematic review and meta-analysis. (July 2018)

• Record Type: Journal Article
• Authors: Arenas, M.; Rodríguez, E.; Sahebkar, A.; Sabater, S.; Rizo, D.; Pallisé, O.; Hernández, M.; Riu, F.; Camps, J.; Joven, J.
• Is Part Of: Critical reviews in oncology/hematology. Volume 127(2018)
• Page Start: 6
• Page End: 14
• Publication Date: 2018-07
• Subjects: ARE arylesterase -- CI confidence interval -- CMA comprehensive meta-analysis -- CRP C-reactive protein -- HDL high-density lipoproteins -- LAC lactonase -- LDL low-density lipoproteins -- PON paraoxonase -- PON1 paraoxonase-1 -- PRISMA preferred reporting items for systematic reviews and meta-analyses -- SD standard deviation -- SEM standard error of the mean -- SMD standardized mean difference -- STARLITE sampling strategy, type of study, approaches, range of years, limits, inclusions and exclusions, terms used, electronic sources -- TSA trial sequential analysis; Meta-analysis -- Oxidative stress -- paraoxonase-1; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2018.04.005
• Languages: English
• ISSNs: 1040-8428

Abstract

Abstract: Purpose: Paraoxonase-1 (PON1) is a lipolactonase implicated in the elimination of carcinogenic free radicals and in the scavenging mechanisms to maintain oxidative balance. The objective of the present systematic review and meta-analysis was to evaluate possible alterations in serum PON1 activity in patients with cancer. Methods: A systematic search of the observational studies in humans published in the last 15 years was performed through Medline databases following the PRISMA and STARLITE statements. Further, a keyword-based computerized search with restrictions on publication date, and a meta-analysis of case-control studies was performed. Results: In total, 23 studies were included most of which reported decreased PON1 activity in patients with cancer. This could indicate impaired defense ability against oxidative stress with potential implications in cell proliferation, promotion of genetic instability, and alterations in cellular sensitivity to chemotherapy. Conclusion: This systematic review and meta-analysis confirms a consistent association between cancer and decreased serum PON1 activities. These findings may open fruitful lines of research with clinical relevance, and an understanding of molecular alterations underlying carcinogenesis.